- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02578030
Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD
May 14, 2021 updated by: Shire
A Phase 1, Open-label Study of the Pharmacokinetics of d- and L-amphetamine After a Single Dose of SHP465 12.5 mg or 25 mg Administered to Children and Adolescents Aged 6 to17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
To provide additional, required information on the pharmacokinetic profile of SHP465 in the targeted population (children and adolescents aged 6-17 years of age with ADHD).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33143
- QPS MRA
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Center for Psychiatry and Behavioral Medicine, Inc.
-
-
Texas
-
Houston, Texas, United States, 77098
- Houston Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 6 to 17 years inclusive at the time of consent/assent. The date of signature of the informed consent/assent is defined as the beginning of the Screening Period. This inclusion criterion will only be assessed at the first screening visit.
- Male, or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol or females of non-childbearing potential.
- Subject meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for a primary diagnosis of ADHD based on an accepted ADHD diagnostic instrument and documented in the subject's medical record. Subject's ADHD is currently adequately controlled with an amphetamine-based product.
- Subject is functioning at an age appropriate level intellectually, as determined by the investigator.
- Must be considered "healthy". Healthy status is defined by absence of evidence of any active or chronic disease other than their ADHD following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, and urinalysis.
- Ability to swallow a capsule of investigational product whole.
Exclusion Criteria:
- Current use of any ADHD medication other than an amphetamine-based product.
- History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gall bladder removal, or current or recurrent disease other than their ADHD
- Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment
- Subject has a current, controlled or uncontrolled, comorbid psychiatric diagnosis with significant symptoms
- Subject meets DSM-V diagnosis of conduct disorder.
- Subject is considered a suicide risk in the opinion of the investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation.
- Subject is underweight based on Centers for Disease Control and Prevention (CDC) body mass index (BMI)- for-age sex-specific values
- Subject is significantly overweight based on CDC BMI-for-age sex specific values
- Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
- Subject has a concurrent chronic or acute illness, disability, or other condition that might confound the results of safety assessments conducted in the study
- Subject has a history of seizure, a chronic or current tic disorder, or a current diagnosis of Tourette's Disorder. Subject has a history of tics that are judged to be exclusionary.
- Subject's blood pressure measurements exceed the 90th percentile for age, sex, and height
- Subject has a known history of hypertension.
- Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
- Subject has any clinically significant ECG or clinically significant laboratory abnormality
- Subject has abnormal thyroid function
- Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any ingredients.
- History of alcohol or other substance abuse within the last year. Subjects with a lifetime history of amphetamine, cocaine, or other stimulant abuse and/or dependence will be excluded.
Use Within 30 days prior to the first dose of investigational product:
- have used an investigational product
- have been enrolled in a clinical study (including vaccine)
- have had any substantial changes in eating habits
- A positive screen for alcohol or drugs of abuse. A positive hepatitis B surface antigen (HBsAg); hepatitis C virus (HCV); or HIV antibody screen.
- Use of tobacco in any form in the last 30 days
- Prior screen failure, enrollment, or participation in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SHP465 12.5 mg
A single dose of SHP465 12.5 mg for Subjects aged 6-12 years
|
|
EXPERIMENTAL: SHP465 25 mg
A single dose of SHP465 25 mg for Subjects aged 13-17 years
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Drug Concentration (Cmax) of Dextroamphetamine (d-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Maximum concentration occurring at time of maximum observed concentration of d-amphetamine during a dosing interval.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Maximum Observed Drug Concentration (Cmax) for Levoamphetamine (l-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Maximum observed concentration of l-amphetamine during a dosing interval.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Time to Reach Maximum Observed Drug Concentration (Tmax) of Dextroamphetamine (d-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Time to reach maximum observed drug concentration of d-amphetamine during a dosing interval.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Time to Reach Maximum Observed Drug Concentration (Tmax) of Levoamphetamine (l-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Time to reach maximum observed drug concentration of l-amphetamine during a dosing interval.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Area Under the Curve From Zero to Infinity (AUC0-infinity) of Dextroamphetamine (d-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
AUC0-infinity was calculated using the observed value of the last non-zero concentration of d-amphetamine in plasma.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Area Under the Curve From Zero to Infinity (AUC0-infinity) of Levoamphetamine (l-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
AUC0-infinity was calculated using the observed value of the last non-zero concentration of l-amphetamine in plasma.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Area Under the Curve From Zero to Last Measurable Concentration (AUClast) of Dextroamphetamine (d-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Area under the curve from the time of dosing to the last measurable concentration of d-amphetamine in plasma.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Area Under the Curve From Zero to Last Measurable Concentration (AUClast) of Levoamphetamine (l-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Area under the curve from the time of dosing to the last measurable concentration of l-amphetamine in plasma.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Terminal Half-life (t½) of Dextramphetamine (d-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Terminal half-life is the time measured for the plasma concentration of d-amphetamine to decrease by one half.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Terminal Half-life (t½) of Levoamphetamine (l-amphetamine) in Plasma
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Terminal half-life is the time measured for the plasma concentration of l-amphetamine to decrease by one half.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Total Body Clearance for Extravascular Administration (CL/F) of Dextroamphetamine (d-amphetamine)
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Total body clearance for extravascular administration of d-amphetamine divided by the fraction of dose absorbed.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Total Body Clearance for Extravascular Administration (CL/F) of Levoamphetamine (l-amphetamine)
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Total body clearance for extravascular administration of l-amphetamine divided by the fraction of dose absorbed.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Volume of Distribution After Extravascular Administration (Vz/F) of Dextroamphetamine (d-amphetamine)
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Volume of distribution for d-amphetamine based on the terminal phase following extravascular administration divided by the fraction of dose absorbed.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Volume of Distribution After Extravascular Administration (Vz/F) of Levoamphetamine (l-amphetamine)
Time Frame: Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Volume of distribution for l-amphetamine based on the terminal phase following extravascular administration divided by the fraction of dose absorbed.
|
Pre-dose, 2, 4, 6, 8, 10, 12, 24, 48, 72 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame: From start of study drug administration up to follow-up (up to 9 days)
|
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
An AE was considered as treatment-emergent (TEAE) if it had a start date and time on or after the dose of investigational product and no later than 72 hours after dosing, or if it had a start date and time before the date and time of the dose of investigational product, but increased in severity on or after the date and time of the dose of investigational product and no later than 72 hours after dosing.
|
From start of study drug administration up to follow-up (up to 9 days)
|
Number of Participants With TEAE Related to Vital signs, Electrocardiogram (ECG), and Clinical Laboratory Tests
Time Frame: From start of study drug administration up to follow-up (up to 9 days)
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Vital signs included blood pressure, pulse rate, respiratory rate, and body temperature.
ECG was analysed as 12-lead ECG.
Clinical laboratory test is considered for biochemistry, Hematology and Urinalysis.
|
From start of study drug administration up to follow-up (up to 9 days)
|
Number of Participants With Suicidal Behavior and / or Ideation ("Yes" Response) on the Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: Baseline up to Day 4
|
C-SSRS is a clinician rated assessment of suicidal behavior and / or intent categorized as: Suicidal behavior=a "yes" response to any of 5 suicidal behavior questions (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide); Suicidal ideation=a "yes" response to any one of 5 suicidal ideation questions which includes wish to be dead, and 4 different categories of active suicidal ideation (thought, thought with method, thought with intent, thought with plan and intent).
|
Baseline up to Day 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 24, 2015
Primary Completion (ACTUAL)
November 10, 2015
Study Completion (ACTUAL)
November 10, 2015
Study Registration Dates
First Submitted
October 5, 2015
First Submitted That Met QC Criteria
October 14, 2015
First Posted (ESTIMATE)
October 16, 2015
Study Record Updates
Last Update Posted (ACTUAL)
May 18, 2021
Last Update Submitted That Met QC Criteria
May 14, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHP465-111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder (ADHD)
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ironshore Pharmaceuticals and Development, IncCompletedAttention-Deficit Hyperactivity Disorder (ADHD)United States
-
Massachusetts General HospitalShireCompletedAttention Deficit/Hyperactivity Disorder(ADHD)United States
-
Medical University of South CarolinaShireCompletedAdult Attention Deficit Hyperactivity Disorder (ADHD)United States
-
Sheba Medical CenterCompletedADHD Predominantly Inattentive Type | Attention Deficit/Hyperactivity Disorder Combined Type | ADHD Predominantly Hyperactivity Type | ADHD-not Other SpecifiedIsrael
-
Cingulate TherapeuticsRho, Inc.CompletedADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder CombinedUnited States
-
Tris Pharma, Inc.Massachusetts General Hospital; Massachusetts Institute of TechnologyCompleted
-
Karolinska InstitutetRegion StockholmCompleted
Clinical Trials on SHP465 12.5mg
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
ShireTerminatedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
GlaxoSmithKlineCompletedChronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, IdiopathicJapan
-
HK inno.N CorporationCompletedHypertensionKorea, Republic of
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.CompletedSolid Tumor | Idiopathic Pulmonary Fibrosis(IPF)China
-
Dong-A ST Co., Ltd.CompletedHypertensionKorea, Republic of
-
HK inno.N CorporationEnrolling by invitationHealthyKorea, Republic of